A source-linked view of every Cotadutide study in the current snapshot—status, phase, enrollment, results, publications, locations and changes over time.
Largest indexed study
834 participants · NCT03235050 →Developer / research origin
AstraZeneca
Evidence summary
Cotadutide appears in 24 indexed studies: 0 recruiting, 22 completed and 12 with registry results posted. The highest registered development stage in this snapshot is Phase 2. These counts measure registry activity; they do not establish that Cotadutide is safe or effective.
Review the design, endpoints, population, protocol changes, statistical analysis and publications before drawing conclusions.
Current studies
Completed studies
Stopped studies
AstraZeneca · Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis
Phase 2
Completed
54
2025-09
AstraZeneca · Non-alcoholic Steatohepatitis · Type 2 Diabetes Mellitus (T2DM)
Phase 1
Completed
10
2025-07
AstraZeneca · Type 2 Diabetes Mellitus · Chronic Kidney Diseases
Phase 2
Completed
248
2025-01
MedImmune LLC · Type 2 Diabetes Mellitus
Phase 2
Completed
51
2024-11
AstraZeneca · Diabetes
Phase 1
Completed
16
2023-11
MedImmune LLC · Diabetes Mellitus, Type II · Obesity
Phase 2
Completed
28
2023-01
AstraZeneca · Non-alcoholic Steatohepatitis
Phase 1
Terminated
31
2023-04
AstraZeneca · Hepatic Impairment
Phase 1
Terminated
24
2023-03
Full study index
Add status, phase, condition, country, result and publication filters inside this molecule’s indexed study set.
24 matching studies
Last registry update first
Latest publications
Related pages
Commercial research listings, where present, are kept separate from clinical evidence and are not treatment recommendations.